Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?

[1]  I. Rupenthal,et al.  Injectable implants for the sustained release of protein and peptide drugs. , 2013, Drug discovery today.

[2]  R. Schneider,et al.  A Complete Physicochemical Identity Card of S-nitrosoglutathione , 2013 .

[3]  P. Leroy,et al.  S-nitrosation/denitrosation in cardiovascular pathologies: facts and concepts for the rational design of S-nitrosothiols. , 2012, Current pharmaceutical design.

[4]  Keith E Maier,et al.  A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. , 2012, Nitric oxide : biology and chemistry.

[5]  K. Mäder,et al.  In situ forming implants - an attractive formulation principle for parenteral depot formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  S. Venkatraman,et al.  Cosolvent effects on the drug release and depot swelling in injectable in situ depot-forming systems. , 2012, Journal of pharmaceutical sciences.

[7]  M. Schoenfisch,et al.  Nitric oxide release: part I. Macromolecular scaffolds. , 2012, Chemical Society reviews.

[8]  Karen Vanhoorelbeke,et al.  Platelets at work in primary hemostasis. , 2011, Blood reviews.

[9]  T. Münzel,et al.  Nitrate therapy: new aspects concerning molecular action and tolerance. , 2011, Circulation.

[10]  J. Benoit,et al.  Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? , 2011, International journal of pharmaceutics.

[11]  Luis Solorio,et al.  Effect of injection site on in situ implant formation and drug release in vivo. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[13]  S. Sortino.  Light-controlled nitric oxide delivering molecular assemblies. , 2010, Chemical Society reviews.

[14]  M. D. de Oliveira,et al.  Poly(vinyl alcohol) films for topical delivery of S-nitrosoglutathione: effect of freezing-thawing on the diffusion properties. , 2010, Journal of biomedical materials research. Part B, Applied biomaterials.

[15]  Chi H. Lee,et al.  In vivo evaluation of vaginal films for mucosal delivery of nitric oxide. , 2009, Biomaterials.

[16]  J. Uetrecht,et al.  D-penicillamine-induced autoimmunity: relationship to macrophage activation. , 2009, Chemical research in toxicology.

[17]  R. Bodmeier,et al.  Injectability of biodegradable in situ forming microparticle systems (ISM). , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  R. Bodmeier,et al.  Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  M. R. Miller,et al.  Recent developments in nitric oxide donor drugs , 2007, British journal of pharmacology.

[20]  R. Bodmeier,et al.  A novel in situ forming drug delivery system for controlled parenteral drug delivery. , 2007, International journal of pharmaceutics.

[21]  M. Meyerhoff,et al.  More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. , 2003, Journal of medicinal chemistry.

[22]  J. Keaney,et al.  The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.

[23]  G. Heusch,et al.  Plasma Nitrosothiols Contribute to the Systemic Vasodilator Effects of Intravenously Applied NO: Experimental and Clinical Study on the Fate of NO in Human Blood , 2002, Circulation research.

[24]  D. Webb,et al.  Nitric oxide donor drugs: current status and future trends , 2002, Expert opinion on investigational drugs.

[25]  D. Webb,et al.  Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. , 2000, European journal of pharmacology.

[26]  A. Ferro,et al.  S-Nitrosothiols: a class of nitric oxide-donor drugs. , 2000, Clinical science.

[27]  K J Brodbeck,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[28]  D. L. Williams,et al.  The Chemistry of S-Nitrosothiols , 1999 .

[29]  P. D. Graham,et al.  Phase inversion dynamics of PLGA solutions related to drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[30]  C. Duvivier,et al.  Vasodilators, aortic elasticity, and ventricular end-systolic stress in nonanesthetized unrestrained rats. , 1997, Hypertension.

[31]  P. Kubes,et al.  Role of nitric oxide in regulation of leucocyte‐endothelial cell interactions , 1997, Experimental physiology.

[32]  S. Moncada,et al.  Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. , 1994, Cardiovascular research.

[33]  J. Stamler,et al.  Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Bottoni,et al.  Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. , 2010, Current medicinal chemistry.

[35]  F. Lee,et al.  Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits. , 1992, The Journal of pharmacology and experimental therapeutics.